LT3505535T - Monokloninis antikūnas prieš pd1, jo farmacinė kompozicija ir panaudojimas - Google Patents
Monokloninis antikūnas prieš pd1, jo farmacinė kompozicija ir panaudojimasInfo
- Publication number
- LT3505535T LT3505535T LTEPPCT/CN2017/098465T LTCN2017098465T LT3505535T LT 3505535 T LT3505535 T LT 3505535T LT CN2017098465 T LTCN2017098465 T LT CN2017098465T LT 3505535 T LT3505535 T LT 3505535T
- Authority
- LT
- Lithuania
- Prior art keywords
- pharmaceutical composition
- monoclonal antibody
- monoclonal
- antibody
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610705763.5A CN106977602B (zh) | 2016-08-23 | 2016-08-23 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| PCT/CN2017/098465 WO2018036472A1 (zh) | 2016-08-23 | 2017-08-22 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3505535T true LT3505535T (lt) | 2025-01-27 |
Family
ID=59340342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/CN2017/098465T LT3505535T (lt) | 2016-08-23 | 2017-08-22 | Monokloninis antikūnas prieš pd1, jo farmacinė kompozicija ir panaudojimas |
Country Status (22)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292449B2 (en) | 2015-03-13 | 2024-02-01 | Cytomx Therapeutics Inc | Nucleic acids encoding anti-pdl1 antibodie and methods of producing same |
| WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CN109425736B (zh) * | 2017-08-25 | 2021-04-09 | 北京百普赛斯生物科技股份有限公司 | 一种检测pd-1抗体血药浓度的方法及试剂盒 |
| SG11202002282TA (en) | 2017-09-20 | 2020-04-29 | Regeneron Pharma | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CN112584901A (zh) * | 2018-04-04 | 2021-03-30 | 真和制药有限公司 | 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物 |
| KR102882368B1 (ko) | 2018-05-07 | 2025-11-07 | 젠맵 에이/에스 | 항-pd-1 항체와 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 |
| JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| CN112566661B (zh) * | 2018-07-18 | 2024-02-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN109053889B (zh) * | 2018-07-25 | 2019-06-21 | 博奥信生物技术（南京）有限公司 | 一种抗人pd1单克隆抗体及用途 |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| US20220175815A1 (en) | 2019-04-03 | 2022-06-09 | Orega Biotech | Combination therapies based on pd1 and il-17b inhibitors |
| CN110373415B (zh) * | 2019-06-12 | 2023-06-09 | 安徽省昂普拓迈生物科技有限责任公司 | 特异性结合pd-l1蛋白的核酸适配体及其用途 |
| TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
| CA3146780A1 (en) * | 2019-08-02 | 2021-02-11 | Akeso Pharmaceuticals, Inc. | Anti-ctla4/anti-pd-1 bispecific antibody and use thereof |
| JP7753186B2 (ja) * | 2019-08-02 | 2025-10-14 | シーティーティーキュー－アケソ（シャンハイ） バイオメド テク カンパニー リミテッド | 抗ｐｄ－１抗体およびその医学的使用 |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| CN110903391B (zh) * | 2019-10-25 | 2021-05-28 | 东大生物技术(苏州)有限公司 | 一组pd-l1单克隆抗体及其医药用途 |
| CN112915202B (zh) * | 2019-12-06 | 2025-08-01 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN113004408B (zh) * | 2019-12-20 | 2022-07-01 | 广东菲鹏制药股份有限公司 | 抗人程序死亡因子-1单克隆抗体 |
| CN113117072A (zh) * | 2020-01-14 | 2021-07-16 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| EP4110810A1 (en) | 2020-02-28 | 2023-01-04 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| BR112022021426A2 (pt) * | 2020-04-22 | 2022-12-13 | Akeso Biopharma Inc | Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73 |
| BR112022022020A2 (pt) | 2020-04-29 | 2023-01-31 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Proteína bifuncional contra pd-1 e tgf-ss |
| CN113754767A (zh) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | 抗人pd-1抗体及其用途 |
| CN114761434B (zh) * | 2020-09-30 | 2023-06-27 | 苏州沙砾生物科技有限公司 | Pd-1抗体及其制备方法与应用 |
| IL302836A (en) | 2020-11-17 | 2023-07-01 | Seagen Inc | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| CN113336848B (zh) * | 2021-02-03 | 2022-08-19 | 上海莱馥医疗科技有限公司 | 一种抗pd-1抗体及其用途 |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| KR20240083095A (ko) | 2021-09-29 | 2024-06-11 | 아케소 바이오파마, 인크. | 항-lag3 항체, 약학 조성물 및 용도 |
| EP4413040A1 (en) | 2021-10-06 | 2024-08-14 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN113912710B (zh) * | 2021-11-17 | 2023-05-26 | 杭州旭科生物技术有限公司 | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 |
| CN114316053B (zh) * | 2021-12-20 | 2023-09-29 | 南京诺唯赞检测技术有限公司 | 一种vce的单克隆抗体及其制备方法 |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| CN119031933B (zh) * | 2022-04-12 | 2025-08-26 | 正大天晴(广州)医药有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
| EP4522654A1 (en) * | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| CA3253038A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY |
| TW202346342A (zh) | 2022-05-13 | 2023-12-01 | 大陸商正大天晴藥業集團南京順欣製藥有限公司 | 抗tim-3抗體與抗pd-1抗體的藥物組合 |
| WO2024051670A1 (zh) * | 2022-09-06 | 2024-03-14 | 正大天晴药业集团股份有限公司 | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |
| EP4598960A1 (en) * | 2022-10-05 | 2025-08-13 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
| CN117986356B (zh) * | 2022-10-27 | 2025-07-22 | 纽迈生物科技(苏州)有限公司 | 一种制备抗体的方法 |
| WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| AU2024271605A1 (en) | 2023-05-12 | 2025-11-13 | BioNTech SE | Antibodies capable of binding to ox40, variants thereof and uses thereof |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| WO2025056014A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| CN118652343B (zh) * | 2024-07-08 | 2025-05-09 | 吉林省医菲尼迪生物医药有限公司 | 一种临床血液免疫细胞以及在治疗疾病中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| ES2367430T3 (es) * | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR20130049775A (ko) | 2010-03-12 | 2013-05-14 | 애브비 바이오테라퓨틱스 인크. | Ｃｔｌａ４ 단백질 및 이의 용도 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| DK2691112T3 (en) * | 2011-03-31 | 2018-07-30 | Merck Sharp & Dohme | STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS |
| PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| EP2890715B1 (en) * | 2012-08-03 | 2020-12-16 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| EP4285928A3 (en) | 2013-09-27 | 2024-03-13 | F. Hoffmann-La Roche AG | Anti-pdl1 antibody formulations |
| HUE046249T2 (hu) * | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| RU2694981C2 (ru) | 2014-01-03 | 2019-07-18 | Ф. Хоффманн-Ля Рош Аг | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104974253A (zh) | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN104987421A (zh) | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| CN105175545B (zh) * | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
| CN105175544B (zh) * | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| CN105754990A (zh) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
-
2016
- 2016-08-23 CN CN201610705763.5A patent/CN106977602B/zh active Active
-
2017
- 2017-08-22 EP EP24206755.1A patent/EP4509186A3/en active Pending
- 2017-08-22 SG SG11201901584UA patent/SG11201901584UA/en unknown
- 2017-08-22 LT LTEPPCT/CN2017/098465T patent/LT3505535T/lt unknown
- 2017-08-22 EP EP17842895.9A patent/EP3505535B1/en active Active
- 2017-08-22 JP JP2019531512A patent/JP7082620B2/ja active Active
- 2017-08-22 SI SI201731577T patent/SI3505535T1/sl unknown
- 2017-08-22 ES ES17842895T patent/ES3001154T3/es active Active
- 2017-08-22 HU HUE17842895A patent/HUE069593T2/hu unknown
- 2017-08-22 US US16/327,083 patent/US12076398B2/en active Active
- 2017-08-22 PT PT178428959T patent/PT3505535T/pt unknown
- 2017-08-22 NZ NZ751902A patent/NZ751902A/en unknown
- 2017-08-22 PL PL17842895.9T patent/PL3505535T3/pl unknown
- 2017-08-22 AU AU2017316255A patent/AU2017316255C1/en active Active
- 2017-08-22 RS RS20250001A patent/RS66372B1/sr unknown
- 2017-08-22 FI FIEP17842895.9T patent/FI3505535T3/fi active
- 2017-08-22 WO PCT/CN2017/098465 patent/WO2018036472A1/zh not_active Ceased
- 2017-08-22 MX MX2019002268A patent/MX2019002268A/es unknown
- 2017-08-22 EA EA201990570A patent/EA201990570A1/ru unknown
- 2017-08-22 KR KR1020197008464A patent/KR102469286B1/ko active Active
- 2017-08-22 BR BR112019003775A patent/BR112019003775A2/pt unknown
-
2019
- 2019-02-21 IL IL264956A patent/IL264956B2/en unknown
- 2019-03-22 ZA ZA2019/01781A patent/ZA201901781B/en unknown
-
2024
- 2024-04-17 AU AU2024202527A patent/AU2024202527A1/en active Pending
- 2024-07-22 US US18/780,086 patent/US20250041409A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3505535T (lt) | Monokloninis antikūnas prieš pd1, jo farmacinė kompozicija ir panaudojimas | |
| IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
| ZA202101894B (en) | Anti-pd-1 and anti-vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| ZA202000113B (en) | Anti-ctla-4 antibodies and uses thereof | |
| ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
| ZA202206885B (en) | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof | |
| PT3476399T (pt) | Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste | |
| ZA201700528B (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| EP3309177A4 (en) | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof | |
| IL271222A (en) | Dosing regimens for anti-tim-3 antibodies and their uses | |
| EP3597735A4 (en) | CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF | |
| EP3464355A4 (en) | MONOCLONAL ANTIBODIES DIRECTED AGAINST DSG2 AND ITS USE | |
| IL274502A (en) | Anti-OX40 antibodies and uses thereof | |
| IL262404A (en) | Antibodies, antibody fragments, and their immunosuppressants against ror2 and their uses | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| ZA201807132B (en) | Humanized anti-basigin antibodies and the use thereof | |
| EP3404042A4 (en) | Monoclonal antibody fnab8 and application thereof | |
| IL266721A (en) | Anti-gp73 antibodies and immunoconjugates | |
| HK40020419A (en) | Dosage regimens for anti-tim-3 antibodies and uses thereof |